Revance Therapeutics, Inc. - FORM 10-K - EX-21.1 - EXHIBIT 21.1 - March 2, 2018

Attached files

file filename
EX-32.2 - EXHIBIT 32.2 - Revance Therapeutics, Inc.rvnc1231201710kex322-certi.htm
EX-32.1 - EXHIBIT 32.1 - Revance Therapeutics, Inc.rvnc1231201710kex321-certi.htm
EX-31.2 - EXHIBIT 31.2 - Revance Therapeutics, Inc.rvnc1231201710kex312-certi.htm
EX-31.1 - EXHIBIT 31.1 - Revance Therapeutics, Inc.rvnc1231201710kex311-certi.htm
EX-23.1 - EXHIBIT 23.1 - Revance Therapeutics, Inc.rvnc1231201710kex231-conse.htm
EX-10.26 - EXHIBIT 10.26 - Revance Therapeutics, Inc.rvnc1231201710kex1026-2018.htm
EX-10.24 - EXHIBIT 10.24 - Revance Therapeutics, Inc.rvnc1231201710kex1024-amen.htm
10-K - 10-K - Revance Therapeutics, Inc.rvnc1231201710k.htm
Exhibit 21.1
REVANCE THERAPEUTICS, INC.
LIST OF SUBSIDIARIES
1. Revance Therapeutics LTD, a wholly owned subsidiary incorporated in England and Wales.
2. Revance International Limited, a wholly owned subsidiary incorporated in the Cayman Islands.



Revance Therapeutics, Inc. Reports